Platinum-Sensitive Ovarian Carcinoma — Trials

Platinum-Sensitive Ovarian Carcinoma — Trials · CancerIndex

Clinical trials

Registered studies

26 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 15
Recruiting: 7
Ph III recruiting: 2
Growth YoY: —
Industry share: 33%
Top sponsor: National Cancer Institute (NCI)
Termination share: —

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (4)

clinicaltrialsPublishedShowing 1–2 of 2 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT03691376	Genetically Engineered Cells (NY-ESO-1 TCR Engineered T Cells and HSCs) After Melphalan Conditioning Regimen in Treating Patients With Recurrent or Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer	terminated	Phase 1	4	Roswell Park Cancer InstituteOTHER	1	Sep 19, 2024	clinicaltrials
NCT04907968	Study of Upifitamab Rilsodotin in Combination With Carboplatin in Participants With High-grade Serous Ovarian Cancer(UPGRADE)	terminated	Phase 1	31	Mersana TherapeuticsINDUSTRY